anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
When PADCEV was given in combination with pembrolizumab, 67% of the 564 patients treated with combination therapy had peripheral neuropathy of any grade, 36% had Grade 2 neuropathy, and 7% had Grade 3 neuropathy. The incidence of peripheral neuropathy occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of Grade ≥2 peripheral neuropathy was 6 months (range: 0.3 to 25 months) [see Adverse Reactions (6.1)]. Of the patients who experienced neuropathy and had data regarding resolution (N = 373), 13% had complete resolution, and 87% of patients had residual neuropathy at last evaluation. Of the patients with residual neuropathy at last evaluation, 45% (146/326) had Grade ≥2 neuropathy.

Peripheral neuropathy occurred in 53% of the 720 patients treated with PADCEV as a single agent in clinical trials including 38% with sensory neuropathy, 8% with muscular weakness and 7% with motor neuropathy. Thirty percent of patients experienced Grade 2 reactions and 5% experienced Grade 3-4 reactions. Peripheral neuropathy occurred in patients treated with PADCEV with or without preexisting peripheral neuropathy. The median time to onset of Grade ≥2 peripheral neuropathy was 4.9 months (range: 0.1 to 20 months). Neuropathy led to treatment discontinuation in 6% of patients [see Adverse Reactions (6.1)]. Of the patients who experienced neuropathy who had data regarding resolution (N = 296), 11% had complete resolution, and 89% had residual neuropathy at the time of their last evaluation. Of the patients with residual neuropathy at last evaluation, 50% (132/262) had Grade ≥2 neuropathy.

Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of PADCEV when peripheral neuropathy occurs. 

Permanently discontinue PADCEV in patients who develop Grade >3 peripheral neuropathy [see Dosage and Administration (2.2)].
The present invention relates to a pharmaceutical composition for preventing or treating influenza virus infection. Influenza is an infectious disease caused by an influenza virus of the Orthomyxovirus family, is also called flu. In the 20th century, there were three global influenza outbreaks caused by novel influenza, killing tens of millions of people. Myxovirus resistance proteins, a type of GTPases, are known to have antiviral effects on infection of various RNA viruses, but do not move smoothly between cells due to their self-aggregation property, and thus are not commercially available as an antiviral agent. Therefore, the present invention has been devised to solve the problems in the related art as described above, and the denatured MxA protein of the present invention has a higher solubility than that of the native MxA protein, and thus moves efficiently between cells and exhibits excellent antiviral activity. Thus, the denatured MxA protein is expected to be widely used in the medical field as a preventive or therapeutic agent for influenza virus infection.
The invention disclosed a kind of spirulina which contains spirulina active peptide, protease and kinas, the preparing method and application is also included in the invention. The spirulina contains all round nutrients and has the function of regulating the body blood fat, but the function is very mild and slow. Besides, there are no reports about the molecular spirulina active peptide, protease and kinas existing in spirulina. The invention has fermented the spirulina with Bacillus subtitles to get spirulina that contains spirulina active peptide, protease and kinas. The detecting results show that the spirulina contains 15-40% (W/W) active peptide, 100-10000U/g protease and 1000-80000FU/g kinas when the water content of the spirulina is lower than 7%. The clinical examination shows that the invention has the function of dissolving thrombus, preventing high viscosity blood disease, and hypertensive disease.
PURPOSE:To prepare the titled drug soluble, dispersible and disintegrable rapidly at a specific pH, by coating a drug with a carboxymethylethylcellulose having a specific degree of neutralization. CONSTITUTION:The disintegrability of carboxymethylethylcellolose (CMEC) at 6.0 pH can be remarkably improved without lowering the disintegration resistance at <=3.0-4.0 pH by partially neutralizing the CMEC. A drug is coated with a CMEC having a neutralization degree of 0.5-15% to obtain the objective enteric drug. The partial neutralization of CMEC can be carried out either by mixing a CMEC suspended in an aqueous coating liquid with a basic substance (e.g. alkali metal) of an amount to enable the neutralization of a part of the CMEC, or by mixing a salt of CMEC and basic substance with free CMEC. It can be administered in the form of tablet, capsule, pill, granule, powder, etc.
FIELD: medicine.SUBSTANCE: invention relates to orthopedic dentistry, and can be used in manufacturing metal-ceramic dental prostheses. Essence of method of obtaining metal-ceramic coatings on the surface of dental prostheses lies in the following: before application of metal layer jet-abrasive processing of internal surface and ionic polishing of external surface of dental prosthesis are carried out; transitive from 5 nm to 20 nm thick sublayer from metal (zirconium) is applied, after that, alternating layers from mixture of metal and ceramics with higher content of ceramics and lower content of ceramics are sputtered, with regulation of component ratio in each layer depending on selected colour of dental prosthesis, facing hard ceramic layer being sputtered the last. Each layer with lower content of ceramics is sputtered from 5 nm to 20 nm thick, the layer with higher content of ceramics being from 30 nm to 70 nm thick. Facing layer is sputtered from 1 mcm to 5 mcm thick. Coating is sputtered to 100 mcm thick. Content of ceramics in layers with higher content of ceramics is not less than 60%, with ratio, %: zirconium (Zr) 5-10, zirconium nitride (ZrN) 0-30, zirconium oxide (ZrO)-the remaining part. Content of ceramics in layers with lower content of ceramics is not more than 20%, with ratio, %: zirconium oxide (ZrO) 0-20, zirconium nitride (ZrN) 0-20, zirconium (Zr) - the remaining part.EFFECT: application of method ensures mechanical hardness, strength and plasticity of coating with its small thickness.5 cl, 2 dwg
Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
OBJECTIVE: To investigate the effect of sevoflurane on neuropathic pain induced by chronic constriction injury (CCI) of sciatic nerve in mice, and to elucidate its mechanism by animal experiments.
METHODS AND RESULTS: Thirty-two C57BL/6 mice were randomly divided into four groups: Sham group, Model group, Control group and Sevoflurane group. First, a mouse model of neuropathic pain was established. Then, the mice in each group were killed on Day 14 after operation to harvest the enlarged lumbosacral spinal cord. In contrast with the Model group, the Sevoflurane group displayed a significantly increased paw withdrawal mechanical threshold (PWMT) and significantly prolonged paw withdrawal thermal latency (PWTL) from Day 5 after operation. The morphological changes of lumbosacral spinal cord were observed by hematoxylin-eosin (HE) staining and transmission electron microscopy. Pathological results showed that sevoflurane reduced nuclear pyknosis in lumbosacral spinal cord tissue, with a large number of mitochondrial crista disappearance and mitochondrial swelling. The results of Western blotting showed that sevoflurane significantly decreased the protein expressions of phosphorylated phospholipase Cγ (p-PLCγ), phosphorylated calcium/calmodulin-dependent protein kinase II (p-CaMKII) and phosphorylated inositol 1,4,5-triphosphate receptor (p-IP3R), and reduced the protein expressions of endoplasmic reticulum (ER) stress proteins glucose-regulated protein 78 (GRP78) and GRP94, oxidative stress-related proteins P22 and P47 and inflammatory factors nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), interleukin-1 β (IL-1β), and tumor necrosis factor-α (TNF-α).
CONCLUSIONS: Sevoflurane inhibits neuropathic pain by maintaining ER stress and oxidative stress homeostasis through inhibiting the activation of the PLCγ/CaMKII/IP3R signaling pathway.
Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
Background and Objectives: End-stage kidney disease (ESKD) is a major risk factor for cardiovascular morbidity and mortality. This study aims to evaluate the contribution of traditional risk factors to the development of coronary artery disease (CAD) in patients on dialysis. Materials and Methods: In this study, 54 patients on dialysis with angina symptoms or a positive exercise stress test underwent coronary angiography. Lesions with obstruction >70% lumen diameter of the coronary artery were considered significant. Traditional risk factors included hypertension, diabetes, smoking, dyslipidemia, age, gender, and time spent on dialysis. Results: Out of 54 participants, 41 (75.92%) were men and 13 (24.07%) women. CAD was present in 34 (62.96%) patients, and 20 (37.03%) patients were without CAD. The average age of the participants was 66.51 years. In the group with CAD, the average age was 69.52 years with an average time spent on dialysis of 2.73 years. In the group without CAD, the average age was 61.40 years with a time spent on dialysis of 2.35 years. Hypertension was present in 92.59% of all participants and 97.05% of those with CAD. Diabetes was present in 41.17 patients with CAD and 40% of those without CAD. Dyslipidemia was present in 76.47 participants with CAD and in 40% of those without CAD. Smoking was noticed in 35.29% of the participants with CAD and 57.14% of those without CAD. Besides hypertension, significant predictors for the development of CAD in patients on dialysis were dyslipidemia (OR 3.698, Cl 1.005-13.608, p = 0.049) and age (OR 1.056, Cl 1.004-1.110, p = 0.033). Conclusions: Among the traditional risk factors, hypertension, dyslipidemia, and age are the predictors for the development of CAD in patients on dialysis. Further large randomized clinical studies are needed to clarify the role of traditional risk factors for CAD in patients with ESKD.
Patients with hypothalamus lesion caused by tumors in the hypothalamic region, such as craniopharyngioma and germ cell tumors, and inflammatory diseases are susceptible to develop severe obesity and diabetes mellitus. The occurrence of hypothalamic obesity in patients after surgery with or without radiotherapy for craniopharyngioma can be as high as 42-66%, and the incidence of type 2 diabetes mellitus of them is twice as much as healthy controls. Treatment of obesity and diabetes mellitus in this population is crucial for increasing morbidity and mortality. However, diet and exercise intervention has been proven useless in previous studies. Safe and effective medicine remains to be developed. Exenatide, a GLP-1 receptor agonist, which play an antihyperglycemic role through a variety of mechanisms, such as enhancing glucose-dependent insulin secretion, increasing beta cell mass and decreasing glucagon secretion, possesses a potent ability to induce satiety, slow gastric emptying and reduce food intake, resulting in weight loss both in diabetics and patients with simple obesity. Previous animal study has already shown GLP-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity. Therefore, the investigators hypothesize exenatide treatment might lead to weight loss in hypothalamic obese patients and improve their glycemic control.
PURPOSE:To prepare an artificial carrier which is chemically and physically homogeneous by forming granulated substance containing both synthetic polyamino acid having free carboxyl group and amino group, and water-soluble polysaccharide through phase separation and making said granulated substance to be insoluble. CONSTITUTION:A synthetic polyamino acid having free carboxyl group and amino group is obtained by a known method. The water-soluble polysaccharide is such that is usable as a polyanion by a general coacervation granulation, e.g., gum arabic or the like. The desired carrier particle is obtained on the basis of a principle of a so-called complex coacervation. In other words, a homogeneous aqueous solution in the concentration range where coacervation of polyamino acid as a polycation and polysaccharide as a polyanion appears is prepared and stirred while pH is adjusted, so that the solution becomes not higher than the isoelectric point of polyamino acid. Coacervate is thus formed. By changing the generated coacervate to be insoluble, the desired carrier particle is obtained.
Abnormalities in glucose metabolism that precede the onset of type 2 diabetes (T2D) activate immune cells, leading to elevated inflammatory factors and chronic inflammation. However, no single-cell RNA sequencing (scRNA-seq) studies have characterized the properties and networks of individual immune cells in T2D. Here, we analyzed peripheral blood mononuclear cells (PBMCs) from non-diabetes and T2D patients by scRNA-seq. We found that CD14 monocytes in T2D patients were in a pro-inflammatory state and intermediate monocytes expressed more MHC class II genes. In T2D patients, cytotoxic CD4 T cells, effector memory CD8 T cells, and γδ T cells have increased cytotoxicity and clonal expansion. B cells were characterized by increased differentiation into intermediate B cells, plasma cells, and isotype class switching with increased expression of soluble antibody genes. These results suggest that monocytes, T cells, and B cells could interact to induce chronic inflammation in T2D patients with pro-inflammatory characteristics.
Citrin deficiency is an autosomal recessive disorder caused by a defect of citrin resulting from mutations in SLC25A13. The clinical manifestation is very variable and comprises three types: neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD: OMIM 605814), post-NICCD including failure to thrive and dyslipidemia caused by citrin deficiency, and adult-onset type II citrullinemia (CTLN2: OMIM 603471). Frequently, NICCD can run with a mild clinical course and manifestations may resolve in the post-NICCD. However, a subset of patients may develop CTLN2 when they become more than 18 years old, and this condition is potentially life-threatening. Since a combination of diet with low-carbohydrate and high-fat content supplemented with medium-chain triglycerides is expected to ameliorate most manifestations and to prevent the progression to CTLN2, early detection and intervention are important and may improve long-term outcome in patients. Moreover, infusion of high sugar solution and/or glycerol may be life-threatening in patients with citrin deficiency, particularly CTLN2. The disease is highly prevalent in East Asian countries but is more and more recognized as a global entity. Since newborn screening for citrin deficiency has only been introduced in a few countries, the diagnosis still mainly relies on clinical suspicion followed by genetic testing or selective metabolic screening. This paper aims at describing (1) the different stages of the disease focusing on clinical aspects; (2) the current published clinical situation in East Asia, Europe, and North America; (3) current efforts in increasing awareness by establishing management guidelines and patient registries, hereby illustrating the ongoing development of a global network for this rare disease.
Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
The invention relates to a medical assistance auditing method and system, and belongs to the field of Internet services. Wherein, this system includes: medical assistance database: and constructing a medical help database according to the medical help items and the historical medical help database. And a user interaction module: the method comprises the steps of acquiring a reception item, reception information and a reception type. And a detection demand matching module: and obtaining a test acceptance set according to the acceptance items, obtaining acceptance results according to the intersection of the test acceptance set and the medical assistance database, and inputting the acceptance results into an auditing process to obtain auditing results. Client terminal and print module: and sending the acceptance result to a client terminal, wherein the client terminal acquires feedback information of a client to obtain a final auditing result, and sends the feedback information to a medical help report printing module, and the medical help report printing module generates a medical help result report. The medical assistance is audited, and the medical assistance efficiency and accuracy are improved.
In prepn. of a crosslinked biopolymer based on collagen by alkaline salt treatment of the eye sclera of animals, homogenisation of the tissue obtd. with an aq. soln. of organic acid until a collagen soln. forms, and then extn. of low-mol. impurities, (a) the collagen soln. freed from impurities is satd. with N2O, (b) the soln. is brought to a concn. of at most 80 wt.% and (c) the soln. is irradiated with ionising radiation at a dose of 0.5-15 kGy until a crosslinked biopolymer forms. - Pref. before irradiation, the collagen soln. is partly degassed by centrifuging for 10-30 mins. at 3-40 x 10 power(3) rpm. In prodn. of an implant, (i) the collagen soln. freed from impurities is brought to a concn. of 0.2-1.3 wt.%, (ii) the soln. is satd. with N2O, (iii) a mould is charged with the soln. and irradiated with ionising radiation at a dose of 0.5-15 kGy, (iv) the implant blank, of crosslinked biopolymer based on collagen, is dialysed for 24-48 hrs. in water, (v) the blank is dried to a moisture content of 30-50 wt.% in the crosslinked biopolymer, and (vi) the blank is given the shape and size of the implant, to ensure complete sealing of wounds to the cornea of corium in eye injuries. Before being charged into the mould, the soln. may be partly degassed by successive freezing and thawing at 20-25 deg.C and centrifuging for 10-60 mins. at 1-2 x10 power(3) rpm. The implant is shaped so that it is a cylinder with tapered end, with a length of 3-5 mm and a dia. of the base of 0.5-4.0 mm.
The efficacy and safety of DEFENCATH for reducing the incidence of CRBSI in patients with kidney failure receiving chronic HD was evaluated in LOCK-IT-100 (referred to as Trial 1, NCT02651428), a randomized, double-blind, active-controlled, multicenter trial.

A total of 806 patients were randomized in a 1:1 ratio to receive either DEFENCATH or heparin (heparin sodium USP 1,000 units/mL, benzyl alcohol 9.45 mg/mL and sodium chloride 9.0 mg/mL) as a CLS. Enrollment in Trial 1 was not limited to patients with specific types of HD catheters. DEFENCATH or heparin was instilled into central venous HD catheters at the end of all dialysis sessions and was withdrawn prior to the initiation of the next dialysis session. The median age of the study population was 63 years (range 21-94 years); 58% identified as males and 63% identified as white. The majority of patients (98%) had HD treatment three times per week, and 48% had their catheter implanted within three months prior to randomization.

A clinical adjudication committee (CAC) assessed the cases of CRBSI. The CAC definition for CRBSI included one positive blood culture (other than for coagulase-negative staphylococci, which required a confirmatory culture) from a peripheral site or either the arterial or venous catheter hub or the arterial or venous dialysis blood line and the patient had to have signs and symptoms of infection and no other apparent source of bloodstream infection.

Results of analyses of CAC-adjudicated CRBSI among the DEFENCATH and heparin groups in all randomized patients who received at least one dose of allocated study CLS are presented in Table 3. Patients in the DEFENCATH group had a lower incidence of CRBSI events compared to patients in the control group.

In total, 5% [18/397] of subjects in the DEFENCATH arm and 5% [21/398] of subjects in the heparin arm died during the trial (difference [DEFENCATH – Heparin]: -0.7% with a 95% CI[-3.7%, 2.3%]).

Among the 9 patients in the DEFENCATH arm with a CAC-adjudicated CRBSI, 1 had a gram-negative organism isolated and 8 had a gram-positive organism isolated; among the 32 patients in the heparin arm with a CAC-adjudicated CRBSI, 14 had a gram-negative organism isolated and 18 had a gram-positive organism isolated.
D 5-17a -Allyl-3b :17b -dihydroxy androstene-3-semidiglycollate is prepared by reacting D 5-17a -allyl-3b :17 b -dihydroxyandrostene with digly-collic acid anhydride in pyridine.  It may be converted to the sodium salt by dissolution in sodium bicarbonate solution and byophilization of the solution. By similar means, starting with 17a - isobutyl - 3b  : 17b  - dihydroxy - androstane, there is obtained 17a -isobutyl-3b :17 b -dihydroxy-androstane-3-semidiglycollate and its sodium salt. Specification 968,870 is referred to.ALSO:Pharmaceutical compositions having antiallergic and/or antianaphylactic activity comprise a carrier and a 3b : 17b -dihydroxy compound of the androstane or D 5-androstene series which has in the 17a -position a C3-7 alkyl, alkenyl or alkynyl group and/or a 3-monoester or a salt of a 3-mono-semi-ester thereof, the esters being formed with a saturated or unsaturated, aliphatic, cycloaliphatic, aromatic or heterocyclic mono- or di-carboxylic acid or with a sulpho-benzoic acid, numerous specific examples of which are given and the salts being those with alkali- and alkaline-earth-metal (including magnesium) cations and with aliphatic, cycloaliphatic and araliphatic amines.  They may be in forms suitable for enteral, parenteral or topical administration, e.g. tablets, dragees, oily or aqueous solutions and suspensions, implants, ointments and creams which comprise conventional pharmaceutical excipients. Specification 968,870 is referred to.